Global Non-Hormonal Alternatives for Menopause Market: Growth, Future Prospects, and Competitive Analysis, 2016 - 2028

With the ever-increasing population of women reaching menopause across the world, the demand for Non-Hormonal Alternatives for Menopause is growing at a rapid pace and has bagged the revenue of USD 7,929 million in 2021. Moreover, the demand for Non-Hormonal Alternatives for Menopause is likely to exhibit rapid CAGR of over 7.5% over the forecast period to reach the valuation of USD 13,465 million in 2028. Meanwhile, cumulative revenue growth opportunity offered by global Non-Hormonal Alternatives for Menopause market is expected to reach over USD 76.5 billion between 2022 and 2028.     

Interesting Facts about Non-Hormonal Alternatives for Menopause Industry

• More than 2 million women reach menopause in U.S. alone and over 40 million worldwide
• Over 60 to 70 percent of women reaching menopause face problems such as hot flashes
• Antidepressants are most widely used to treat hot flashes
• S. accounted for over 30% share of the revenue generated by Non-Hormonal Alternatives for Menopause market
• Europe second leading market for Non-Hormonal Alternatives for Menopause

Risk Associated with Hormonal Replacement Therapy to Drive the Demand for Non-Hormonal Alternatives for Menopause

Despite of its efficiency, hormonal replacement therapy is not considered as a first choice of treatment for menopause in women. The reason being hormonal replacement therapy has been considered as a potential risk for development of breast cancer in women. Ever since, a study published by Women’s Health Initiative, physicians have become reluctant to prescribe hormonal replacement therapy. As of now, over two third women facing such problems are given with Non-Hormonal Alternatives for Menopause symptoms.

Antidepressants to Trigger the Growth of Non-Hormonal Alternatives for Menopause     

Selective serotonin reuptake inhibitors (SSRIs), Selective serotonin-norepinephrine reuptake inhibitors (SNRIs), Plant-derived estrogens (phytoestrogens), Herbal treatments, Over-the-counter therapies and Others are major therapies used for the treatment of menopause. Non-hormonal treatments for vasomotor symptoms include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs), which reduce HF severity and frequency by 20 to 65 percent. Since HFs are considered to be caused by alterations in thermoregulation caused by oestrogen shortage, which leads to a drop in serotonin levels, the blockade of serotonin and norepinephrine receptors induced by SSRIs and SNRIs may help to counteract this imbalance. Despite the fact that several studies have examined the efficacy of SSRIs and SNRIs in lowering HFs, paroxetine salt 7.5 mg/day is the only FDA-approved medicine for the treatment of moderate-to-severe vasomotor symptoms in postmenopausal women.

Hot Flashes to Drive the Demand for Non-Hormonal Alternatives for Menopause

Hot Flashes, Vaginal Dryness and Others (Chills, Night Sweats, Sleep Problems, Mood Changes, etc.0 are some of the major indications that drive the demand for Non-Hormonal Alternatives for Menopause. Hot flashes are most common of all menopause symptoms and it affects over 85% women who are going through menopause symptoms. While vaginal dryness account for the second largest share in revenue generated by the Non-Hormonal Alternatives for Menopause market. It is also expected to exhibit rapid growth over the forecast period.

Asia Pacific to Witness Rapid Growth in Demand for Non-Hormonal Alternatives for Menopause

Strong growth in demand for Non-Hormonal Alternatives for Menopause in China, India, South Korea and Japan is leading the growth of Asia Pacific market. Huge population of women in China and India and large number of women reaching menopause every year coupled with increasing health awareness and growing per capita expenditure on healthcare in the region is another factor fueling the growth of Non-Hormonal Alternatives for Menopause. While, U.S. is leading market for Non-Hormonal Alternatives for Menopause with over 25% share in global Non-Hormonal Alternatives for Menopause market. High level of awareness, higher spending power, higher penetration of alternative therapies, etc. is mainly responsible for the strong growth of Non-Hormonal Alternatives for Menopause in U.S. Similarly, Europe also holding significant position in global Non-Hormonal Alternatives for Menopause market. Germany, UK and France are leading overall growth of European Non-Hormonal Alternatives for Menopause market.

Strong Product Pipeline and Focus on Innovation to Propel the Future Growth of Non-Hormonal Alternatives for Menopause    

Swor Women's Care, Paladin Labs, Boehringer Ingelheim, Pfizer, Organon Inc., Lupin and GSK are some of the leading players in global Non-Hormonal Alternatives for Menopause market. There are large number of players operating in the global Non-Hormonal Alternatives for Menopause market. Key players have invested huge amount of sum on the development of new therapies for menopause. There is strong pipeline of Non-Hormonal Alternatives for Menopause. Banking on their strong R&D capabilities, companies are thriving to bring innovative alternatives to hormonal therapies with no compromise in their efficiency.

Frequently asked questions about global Non-Hormonal Alternatives for Menopause industry